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Background: Squamous cell scrotal carcinoma (SCSC) is an infrequent skin cancer associated historically with occupational
carcinogens. Human papillomavirus (HPV) DNA has been associated with SCSC but there is no definitive proof of its oncogenic role.
Methods: Human papillomavirus-DNA and –E6*I mRNA were analysed in six invasive histologically typed SCSC. LCM-PCR was
used to localise HPV DNA to tumour cells. P16INK4aand p53 expression were studied by immunohistochemistry.
Results: In three warty or basaloid SCSC HPV16-DNA and E6*I-mRNA were detected. LCM-PCR confirmed HPV16 was in p16INK4a-
positive malignant cells. However, of three usual-type SCSC, all were HPV-negative and two expressed p53 protein but not
p16INK4a.
Conclusions: Human papillomavirus 16 was present in tumour cells and oncogenically active in basaloid and warty SCSC, whereas
usual SCSC was HPV-negative and showed immunostaining, suggesting p53 mutation. The dual pathways of oncogenesis and
relation between histological type of SCSC and HPV are similar to that in penile cancers.
Squamous cell scrotal cancer (SCSC) is a rare malignancy and was
the first cancer associated with occupational carcinogens including
soot, lubricating and cutting oils (Melicow, 1975; Sorahan et al,
1989). Since the 1970s, occupational-related SCSC incidence has
decreased in the United Kingdom as working conditions have
improved (Sorahan et al, 1989). More recent reports, however,
indicate a steady incidence in the Netherlands and increasing
incidence in the USA (Wright et al, 2008; Verhoeven et al, 2010).
Other factors may be involved.
Human papillomaviruses (HPV) play an important aetiological
role in many anogenital and oropharyngeal carcinomas (http://
www.hpvcentre.net) and have been occasionally linked to skin
tumours outside the genital region (Riddel et al, 2011). Human
papillomavirus-DNA has been found in tissue sections containing
SCSC, precancers and normal scrotum, but biological evidence is
missing that directly demonstrates type-specific HPV-DNA in
tumour cells, producing oncogenic RNA transcripts (Guran and
Pak, 1999; Nielson et al, 2009; Matoso et al, 2014, 2016). We tested
6 cases for 72 mucosal and cutaneous HPV-genotypes. If
HPV-DNA was detected, laser-capture microdissection-PCR
(LCM-PCR) was performed to assign or not an individual HPV
type specifically to cancer cells as we have done for cervical
(pre)-cancer and other HPV-related cancers (Quint et al, 2012;
Guimera et al, 2013; Marı́a José Fernández-Nestosa et al, 2017).
Viral transcriptional activity was confirmed by detection of viral
E6*I oncogene mRNA. Immunohistochemical (IHC) expression of
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p16INK4a was also studied as in previous studies, and is a sensitive
but not specific marker of oncogenic HPV-E7 gene activity. IHC
expression of p53 was analysed as an indicator that p53 mutations
may play a causal role in the development of HPV-negative scrotal
cancers.
MATERIALS AND METHODS
Case selection. Formalin-fixed paraffin-embedded (FFPE) tissue
blocks of six cases of invasive SCSC were collected from Spain
(n¼ 2), Australia (n¼ 2) and Nigeria (n¼ 2) (Table 1). Local and
Catalan Institute of Oncology ethics committees approved all
protocols and an international steering committee oversaw study
progress.
Histology and immunohistochemistry. Cases were sectioned
using a sandwich technique (de Sanjose et al, 2010; Guimera
et al, 2013). At least four pathologists evaluated the haematoxylin-
eosin (H&E) slides, reaching a consensus diagnosis of the
histological type of SCSC: Warty, basaloid or usual. This
classification was based on the criteria defined for penile
carcinomas by the WHO (Moch et al, 2016). P16INK4a staining
was performed on one FFPE-section (4mm) (Guimera et al, 2013)
and was considered positive if more than 50% of tumour cells
showed expression. P53 staining was performed (Halec et al, 2014)
and a tumour was considered driven by p53 mutation if 475% of
the tumour cells showed p53 expression.
Laser capture microdissection (LCM). Human papillomavirus
detected in whole tissue section was localized to tumour cells by
LCM-PCR (Quint et al, 2012). A polyethylene-napthalate (PEN)-
membrane slide, stained only with Hematoxylin was used to
optimise sensitivity.
DNA isolation and HPV-DNA genotyping. The DNA was
isolated using proteinase K solution and HPV-DNA was tested
with the SPF10-DEIA-LiPA25 system (SPF10 -HPV-LiPA, version1
(Labo-Bio-Medical Products, Rijswijk, the Netherlands) (Kleter
et al, 1998, 1999; Quint et al, 2012). In all samples, the endogenous
human gene RNaseP served as a positive amplification control
using real time PCR (Luo et al, 2005). On whole tissue sections, the
HPV genotype detected was confirmed by sequencing of the SPF10
inter-primer region (Geraets et al, 2012). As SPF10 is based on viral
L1 open reading frame (ORF) cases were also analysed with MPTS
123 PCR-Luminex assay (van Alewijk et al, 2013) to detect the
HPV E6 ORF from 16 different genotypes. The presence of
cutaneous HPV from five genera was evaluated by Beta HPV assay
(25 beta HPV genotypes) and Cutaneous Wart-Associated HPV
(23 alpha, gamma, mu and nu genotypes) assays (de Koning et al,
2006, 2010). The presence of 72 HPVs was analysed for L1, E1 or
E6 HPV ORFs.
RNA isolation and E6*I mRNA detection. RNA extraction,
HPV16 E6*I mRNA Reverse Transcription (RT)-PCR and luminex
genotyping system were used as previously described (Halec et al,
2013). An endogenous human transcript, ubiquitin C (ubC) served
as a positive amplification control (Halec et al, 2014).
RESULTS
All six cases were primary SCSC (Table 1). One primary
basaloid SCSC showed metastases at presentation. No cases were
immuno-compromised.
One warty and two basaloid SCSC (case 3, 5 and 6) contained
HPV16 DNA as a single infection by both L1 and E6 ORFs assays.
E6*I mRNA assay confirmed the presence of HPV16 E6*I
transcripts and immunohistochemistry showed diffuse staining
for p16INK4a, while p53 was negative. Moreover, LCM-PCR
localised HPV16 DNA only in the invasive tumour (Table 1 and
Figure 1). From one case with HPV-positive basaloid carcinoma
(case 6), HPV16 was confirmed in metastases in three inguinal
lymph nodes.
In the three usual-type SCSC specimens (case 1, 2 and 4), no
HPV DNA or RNA was detected although quality controls
confirmed the presence of human DNA and RNA. In HPV-
DNA-negative cases 1 and 4, p53 was expressed in 475% of cancer
cells and p16INK4a was completely negative (Table 1 and Figure 2).
In case 2, p53 was expressed in around 25% of cancer cells and
p16INK4a was expressed only patchily (Table 1 and Figure 2).
The median age at diagnosis was 59 years (range: 42–66 years) for
HPV-positive cases and 62 years for HPV-negative cases (range:
46–71 years).
Table 1. invasive scrotal cancers by country, year of/age at diagnosis, histological category, HPV DNA detection and genotyping
by 4 assays, HPV histological localization by LCM, HPV16 E6*I mRNA detection, p16INK4a and p53 overexpression
Cases studied
1 2 3 4 5 6
Country of origin Spain Spain Australia Australia Nigeria Nigeria
Year of diagnosis 2003 2008 2002 2007 2007 2015
Age at diagnosis 71 62 59 46 42 66
Histological diagnosis Usual SCC Usual SCC Warty SCC Usual SCC Basaloid SCC Basaloid SCC
HPV DNA and RNA analysis
SPF10
DEIA-LiPA25 HPV negative HPV negative HPV16 HPV negative HPV 16 HPV 16
MPTS123-PCR Luminex HPV negative HPV negative HPV 16 HPV negative HPV 16 HPV 16
Beta HPVs assay HPV negative HPV negative HPV negative HPV negative HPV negative HPV negative
Cutaneous Wart-Associated HPVs HPV negative HPV negative HPV negative HPV negative HPV negative HPV negative
HPV16 E6*I mRNA-Luminex HPV negative HPV negative Positive HPV negative Positive Positive
DNA and RNA quality control Positive Positive Positive Positive Positive Positive
Laser capture microdissection
Localization of HPV n.a. n.a. SCC n.a. SCC SCC
Immunohistochemistry analysis in primary cancer cells
p16INK4a overexpression o5% 25% 475% o5% 475% 475%
p53 overexpression 475% o25% o25% 475% o25% o25%a
Abbreviations:  ¼negative; SCC¼well differentiated squamous cell carcinoma; n.a.¼ not applicable.
aPoor slide quality made difficult the analyses.
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DISCUSSION
Treatments for skin diseases (for example, arsenic and light
therapies-UVA/UVB radiation) and HPV have been identified as
possible carcinogens to explain the continuing occurrence of SCSC
(Stern, 1990; Andrews et al, 1991; Guran and Pak, 1999; Matoso
et al, 2016). Previous studies have found HPV-DNA in tissue
specimens of SCSC. The current study demonstrates that HPV16 is
present specifically in tumour cells of warty and basaloid type SCSC,
where it is expressing the HPV-E6 oncogene. In addition, these
HPV-positive SCSC show strong expression of p16INK4a. The
specific localisation of HPV16 to SCSC tumour cells required the use
of LCM-PCR, which excluded potential contamination from
adjacent tissue as has been described in studies of cervical cancer
and precancer and of penile cancer (Quint et al, 2012; Guimera et al,
2013; Marı́a José Fernández-Nestosa et al, 2017). The very sensitive
and specific methodology for HPV-DNA detection (Kleter et al,
1998, 1999; Quint et al, 2012), employed in this study together with
more specific data on viral transcriptional activity than p16INK4a
staining provides new definitive evidence confirming the oncogenic
role of HPV16 in some histological types of SCSC (Orihuela et al,
1995; Guran and Pak, 1999; Matoso et al, 2014, 2016).
In two out of three HPV-negative cases of usual type SCSC, p53
was expressed in 475% of the cancer cells indicating the presence
of a mutation in this tumour suppressor gene, but p16INK4a was not
expressed strongly.
This study clearly demonstrates the two separate aetiological
pathways for SCSC suggested previously (Matoso et al, 2014):
Human Papillomavirus and non-HPV related, associated with
separate histological tumour types. The same pattern has been
described by our group using LCM-PCR in penile neoplasia
(Marı́a José Fernández-Nestosa et al, 2017) and is also seen in
vulvar carcinomas, where the HPV prevalence is 33% and 29%,
respectively (de Sanjose et al, 2013; Alemany et al, 2016).
The association between histology and HPV in SCSC appears
the same as that described in penile carcinoma and precancer
where neoplasia related to HPV shows a warty/basaloid histology
and differentiated PeIN and usual squamous cancer is associated
with a HPV-unrelated pathway. In SCSC, HPV16 is the
predominant genotype as in all non-cervical sites such as penile,
vulval, vaginal, anal or oropharyngeal tumours (de Sanjose et al,
2013; Alemany et al, 2014, 2016; Castellsague et al, 2016).
Human papillomavirus16 is also predominant in other cutaneous
in situ or invasive SCC outside the genital area such as in
periungual and/or subungual skin from immunocompetent
patients (Riddel et al, 2011). Scrotal cancer like external vulvar
cancer arises in an epithelium that is morphologically genital
skin. The embryologic differentiation of scrotal cells resembles that
of the vulvar labia majora in women, and may have
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Figure 1. H&E histological images, p16INK4a and p53 expression pattern of the three HPV16 associated scrotal cancers. The quality of Case C
was very poor and the expression of p53 was difficult to analyse.
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the same stem-like cells vulnerable to HPV16 infection (Moore
et al, 2013).
Although limited by the small number of cases, this study
provides biological evidence of an aetiological relationship between
HPV16 and SCSC. Larger epidemiological studies are needed to
determine if other HPV types apart from HPV16 are involved, the
relative role of HPV compared to other environmental and genetic
factors and the possible changing role of HPV in scrotal
carcinogenesis. Such studies could also determine the potential
impact on scrotal cancer of HPV vaccines. Studies of the
mechanism and transformation of the scrotal cells by HPV would
also contribute to understanding why these events are rare
compare to other genital sites, particularly the cervix.
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